RESUMEN
Objective: To observe the clinical efficacy and adverse reactions of apatinib in advanced gastric cancer after routine chemotherapy. Methods: Thirty-one patients with unrespectable stage IV gastric cancer and had a deterioration or recurrence after at least 2 cycles of chemotherapy with thymidine phosphorylase-based regimen, were recruited in this study. The patients were given with 500-250mg of apatinib once daily till disease progression. A chest and abdomen CT or MRI scan was taken every 2 cycles for a response assessment. Results: Among the 31 patients, no one achieved complete response, 7 patients (22.6%) had partial response, 17 patients (32.3%) had stable disease; the disease control rates was 54.8%. The median time to progression was 4.0 months [95% confidence interval (CI): 3.2-4.8]. The median survival time was 5.3 months (95% CI: 3.2-7.4). The main adverse reactions were hypertension, hand foot syndrome, diarrhea, fatigue, proteinuria and liver function damage. Conclusion: Apatinib can obtain good clinical effect in treatment of advanced gastric cancer after chemotherapy resistant.